Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 48

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 48
---
AR Board, rather than an acceptable endpoint . A Board focused on maximizing long - term shareholder value might be expected to… seek improved terms from Alcon — or to invite competing proposals that reflect STAAR’s strategic scarcity, potential synergies, and credible independent worth. To settle for less clearly leaves substantial value unavailable to shareholders and represents a significant gift to Alcon …” 2 Pascal Aeschlimann and David Bailey Former Area Manager, Asia & Middle East and Former CEO and President STAAR Surgical

Broadwood Partners, L.P. Better Alternatives Exist for Stockholders 68 Reject the transaction Reconstitute the Board and management team as necessary Potential for significant value creation as a standalone company, with strategic optionality once the Company is in a stronge r p osition ▪ Broadwood stands ready to support the Company with the recruiting and nomination of new directors and executives, if necessary ▪ Ramp up production at the Company’s new Switzerland facility and continue working with partners in China to optimize inventory levels ▪ Continue the work of the Capital Stewardship Committee to refine the Company’s capital allocation strategy ▪ Further reduce SG&A ▪ Launch EVO+ lens and localize manufacturing in China ▪ The Company’s continued recovery, along with a more cooperative macroeconomic environment, could support a significantly higher valuation in a sale ▪ Alternatively, the Company is well positioned to drive long - term value for stockholders as an independent company Continue to execute strategic initiatives and return the Company to growth Reevaluate strategic alternatives from a position of strength

Broadwood Partners, L.P. STAAR Has a Bright Future as a Standalone Company 69 There are many reasons to be optimistic about STAAR’s prospects as an independent company if the Proposed Merger is rejected ▪ STAAR’s EVO ICLs offer many advantages over competing treatments, including a lower likelihood of dry eye, a shorter recovery ti me, removability and UV protection ▪ Recent data demonstrating the superiority of ICLs indicate that ICLs are poised to become the dominant choice for patients an d s urgeons Leading Technology ▪ ICLs have dominant market share in Japan (70%+), strong market share in China and growing market share in large markets like the United States ▪ While sales in China have been temporarily impacted by softened consumer demand, growth in other markets (e.g., Americas and EME A) remains robust ▪ The Company expects sales in China to normalize in the second half of 2025; we believe the forthcoming launch of the Company